目的:观察中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的临床疗效.方法:将临床196例原发性胆汁性肝硬化患者分为2组,对照组95例,采用常规对症疗法(保肝、解毒、利尿、抗菌)；治疗组101例,在对症疗法的基础上加服中等剂量的熊去氧胆酸.2组均以1个月为1个疗程,3个疗程后观察2组治疗效果和肝功能检查结果.结果:3个疗程后,治疗组的总有效率(79.2％)显著高于对照组(60.0％),差异有统计学意义(P＜0.01)；肝功能检测结果显示,治疗组患者的丙氨酸氨基转移酶、天冬氨酸氨基转移酶显著降低(P＜0.01),接近正常水平；谷酰转肽酶、碱性磷酸酶指标虽然没有恢复到正常范围,但与治疗前比较均有所降低(P＜0.01).结论:中等剂量熊去氧胆酸对原发性胆汁性肝硬化临床疗效显著.%OBJECTIVE: To observe clinical efficacy of moderate dose of ursodeoxycholic acid for primary biliary cirrhosis. METHODS: 196 patients with primary biliary cirrhosis were divided into 2 groups. 95 cases in the control group were given routine symptomatic therapy (liver protection, detoxification, diuretic, antibacterial). 101 cases in treatment group were additionally given moderate dose of ursodeoxycholic acid on the basis of symptomatic therapy. A course of treatment lasted for 1 month. The therapeutic efficacy and liver function of 2 groups were investigated after 3 treatment courses. RESULTS: After 3 treatment courses, total effective rate of treatment group (79.2%) was significantly higher than that of control group (60.0%), there was statistical significance (P<0.01); Results of liver function test showed that ALT and AST of treatment group decreased significantly (P< 0.01), was close to normal levels, GGB, ALT and TBA index hadn't returned to normal range, but was lower than before treatment (P<0.0l). CONCLUSION: The medium dose of ursodeoxycholic acid has obvious effect on primary biliary cirrhosis.
展开▼
